Monoclonal antibody · Antagonist of Granulocyte-macrophage colony-stimulating factor (CSF2) · developed by Kinevant Sciences GmbH
Phase 2Most advanced trial (none active)
1Registered trials
What is Gimsilumab?
Gimsilumab is a fully human IgG1 monoclonal antibody that binds and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), preventing it from reaching its target inflammatory cells and thereby limiting immune cell activation and cytokine release. It is being studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.